Clinical outcomes of everolimus- and zotarolimus-eluting stents in patients with acute myocardial infarction for small coronary artery disease

Journal of Cardiology

Volumn 63, Issue 6, 2014, Pages 409-417

  Cho, Sang Cheol ^a   Jeong, Myung Ho ^b   Kim, Wan ^a   Ahn, Youngkeun ^b   Hong, Young Joon ^b   Kim, Young Jo ^c   Kim, Chong Jin ^d   Cho, Myeong Chan ^e   Han, Kyoo Rok ^f   Kim, Hyo Soo ^g  

^a Gwangju Veterans Hospital   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Young Nam University Hospital   (South Korea)

^d Kyung Hee University College of Medicine   (South Korea)

^e Chungbuk National University Hospital   (South Korea)

^f Hallym University College of Medicine   (South Korea)

^g Seoul National University Hospital   (South Korea)

Author keywords

Everolimus eluting stent; Small coronary artery disease; Zotarolimus eluting stent

Indexed keywords

ENDEAVOR ZES; EVEROLIMUS; PROMUS EES; UNCLASSIFIED DRUG; ZOTAROLIMUS; RAPAMYCIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HOSPITAL DISCHARGE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PROPENSITY SCORE; SMALL CORONARY ARTERY DISEASE; STENT THROMBOSIS; TREATMENT OUTCOME; ZOTAROLIMUS ELUTING STENT; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOLOGY; RADIOGRAPHY; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPENSITY SCORE; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902175785     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.10.016     Document Type: Article

References (31)

1. Keely E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13-20.
2. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schulder G., Barragan P., Guagliumi G., Molnàr F., Falotico R. Randomized study with the sirolimus-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780. RAVEL Study Group.
3. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323. SIRIUS Investigators.
4. Hong Y.J., Jeong M.H., Ahn Y., Kang J.C. The efficacy and safety of drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction (KAMIR). Int J Cardiol 2013, 163:1-4.
5. Suzuki H. Safety and efficacy of drug-eluting stents in patients with acute myocardial infarction-from first generation to second generation of drug-eluting stents. J Cardiol 2013, 61:378-379.
6. Fajadet J., Wijns W., Laarman G.J., Kuck K.H., Ormiston J., Münzel T., Popma J.J., Fitzgerald P.J., Bonan R., Kuntz R.E., Kuntz R.E. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006, 114:798-806. ENDEAVOR II Investigators.
7. Gershlick A., Kandzari D.E., Leon M.B., Wijns W., Meredith I.T., Fajadet J., Popma J.J., Fitzgerald P.J., Kuntz R.E. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007, 100:45M-55M. ENDEAVOR Investigators.
8. Wiemer M., Serruys P.W., Miquel-Hebert K., Neumann F.J., Piek J.J., Grube E., Haase J., Thuesen L., Hamm C. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter Cardiovasc Interv 2010, 75:997-1003.
9. Sugihara M., Miura S., Nishikawa H., Ike A., Mori K., Iwata A., Kawamura A., Saku K. Characteristics of patients and types of lesions in patients with drug-eluting or bare-metal stent implantation in small coronary arteries. J Cardiol 2013, 61:117-121.
10. Schunkert H., Harrell L., Palacios I.F. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1999, 34:40-48.
11. Elezi S., Kastrati A., Neumann F.J., Hadamitzky M., Dirschinger J., Schömig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998, 98:1875-1880.
12. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., Popma J.J., Russell M.E. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004, 109:1942-1947. TAXUS-IV Investigators.
13. Mauri L., Orav E.J., Kuntz R.E. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005, 111:3435-3442.
14. Pocock S.J., Lansky A.J., Mehran R., Popma J.J., Fahy M.P., Na Y., Dangas G., Moses J.W., Pucelikova T., Kandzari D.E., Ellis S.G., Leon M.B., Stone G.W. Angiographic surrogate endpoints in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008, 51:23-32.
15. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012, 60:1581-1598. Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction.
16. Kastrati A., Schömig A., Elezi S., Dirshinger J., Mehilli J., Schühlen H., Blasini R., Neumann F.J. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999, 100:1285-1290.
17. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., McFadden E., Lansky A., Hamon M., Krucoff M.W., Serruys P.W. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351. Academic Research Consortium.
18. Hannan E.L., Zhong Y., Wu C., Walford G., Holmes D.R., Jacobs A.K., Stamato N.J., Venditti F.J., Sharma S., Fergus I., King S.B. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State. Catheter Cardiovasc Interv 2013, 81:1097-1105.
19. Serruys P.W., Silber S., Garg S., van Geuns R.J., Richardt G., Buszman P.E., Kelbaek H., van Boven A.J., Hofma S.H., Linke A., Klauss V., Wijns W., Macaya C., Garot P., DiMario C., et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010, 363:136-146.
20. Stefanini G.G., Serruys P.W., Silber S., Khattab A.A., van Geuns R.J., Richardt G., Buszman P.E., Kelbæk H., van Boven A.J., Hofma S.H., Linke A., Klauss V., Wijns W., Macaya C., Garot P., et al. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents, a substudy of the RESOLUTE All Comers Trial (A randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol 2011, 57:2221-2232.
21. Silber S., Windecker S., Vranckx P., Serruys P.W. Unrestricted randomized use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers Trial. Lancet 2011, 377:1241-1247.
22. von Birgelen C., Basalus M.W., Tandjung K., van Houwelingen K.G., Stoel M.G., Louwerenburg J.H., Linssen G.C., Saïd S.A., Kleijne M.A., Sen H., Löwik M.M., van der Palen J., Verhorst P.M., de Man F.H. A randomized controlled trial in second-generation zotarolimus-eluting resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012, 59:1350-1361.
23. Bangalore S., Kumar S., Fusaro M., Amoroso N., Attubato M.J., Feit F., Bhatt D.L., Slater J. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117,762 patient-years of follow-up from randomized trials. Circulation 2012, 125:2873-2891.
24. Chen K.Y., Rha S.W., Wang L., Li Y.J., Li G.P., Poddar K.L., Park J.Y., Choi C.U., Park C.G., Seo H.S., Oh D.J., Jeong M.H., Ahn Y.K., Hong T.J., Kim Y.J., et al. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis. JACC Cardiovasc Interv 2012, 5:936-945. KAMIR Investigators.
25. Hermiller J.B., Fergus T., Pierson W., Su X., Sood P., Sudhir K., Stone G.W. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial. Am Heart J 2009, 158:1005-1010.
26. Bartorelli A.L., Serruys P.W., Miquel-Hébert K., Yu S., Pierson W., Stone G.W. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III Trials. Catheter Cardiovasc Interv 2010, 76:60-66. SPIRIT II SPIRIT III Investigators.
27. Ito H., Hermiller J.B., Yaqub M., Newman W., Sood P., Wang J.C., Cannon L., Maddux J.E., Sudhir K., Stone G.W. Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV Clinical Trials. J Interven Cardiol 2011, 24:505-513.
28. Hong S.J., Ahn C.M., Lim D.S., Park J.H. Comparison of angiographic and clinical outcomes among patients with sirolimus-, paclitaxel-, zotarolimus- and everolimus-eluting stent implantation in small coronary target vessels and long lesions. J Am Coll Cardiol 2012, 60:B187-B188.
29. Baber U., Mehran R., Sharma S.K., Brar S., Yu J., Kim H.S., Park S.J., Kastrati A., de Waha A., Krishnan P., Moreno P., Sweeny J., Suleman J., Pyo R., Wiley J., et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011, 58:1569-1577.
30. Brilakis E.S., Patel V.G., Banerijee S. Medical management after coronary stent implantation: a review. JAMA 2013, 310:189-198.
31. Räber L., Windecker S. Current status of drug-eluting stents. Cardiovasc Ther 2011, 29:176-189.